Heterogeneity in tumor vasculature gives rise to variability in vascular permeability, one of the consequences being non-uniform intra-tumoral uptake and distribution of nanoparticle-based chemotherapeutics. An imaging agent that can assess tumor vascular heterogeneity and monitor uptake and distribution of nanoparticles could be useful for guiding and monitoring nanoparticle-based chemotherapy. In this work, we demonstrate, in orthotopic mouse models of solid tumors, that a high T1 relaxivity liposomal-gadolinium contrast agent (liposomal-Gd) enables MR imaging of nanoparticle uptake and 3D intra-tumoral distribution at clinically-relevant MR field strength.
This abstract and the presentation materials are available to members only; a login is required.